Search | Clinical Trials Finder

Conditions: Major Depressive Disorder
Interventions: AZD6765 iv, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Chino, California • Lond Beach, California • San Diego, California + 30 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 44
States / cities: Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more

Conditions: Covid19
Interventions: BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB; Biological
Lead sponsor: Sohail Rao; Other
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Edinburg, Texas • Rio Grande City, Texas

Conditions: Abortion, Dilation and Evacuation, Hemorrhage, Prophylactic Tranexamic Acid Use, Blood Loss
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: San Diego, California • Chicago, Illinois

Conditions: Cutaneous T-cell Lymphoma
Interventions: Vitamin B12, Folic Acid, Pralatrexate; Dietary Supplement · Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 10
States / cities: Duarte, California • Redwood City, California • New Haven, Connecticut + 6 more

Conditions: Non-small Cell Lung Cancer
Interventions: Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo; Biological · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 1,513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 49
States / cities: Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more

Conditions: Eosinophilic Asthma
Interventions: Etokimab, Placebo; Biological · Drug
Lead sponsor: AnaptysBio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Normal, Illinois • Novi, Michigan • Edmond, Oklahoma + 1 more

Conditions: Spinal Fusion Acquired, Spinal Stenosis, Lesions of Lumbosacral Intervertebral Disc, Spinal Diseases
Interventions: Dexmedetomidine, 0.9% Saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: End Stage Heart Disease, Right Ventricular Dysfunction
Interventions: inhaled nebulized milrinone; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Blood Loss, Surgical
Interventions: Trasylol (Aprotinin, BAYA0128), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 12
States / cities: Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 8 more

Conditions: Sepsis, Septic Shock, Metabolic Disturbance
Interventions: vitamin C, vitamin B1, hydrocortisone, Normal saline; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Phoenix, Arizona • Boston, Massachusetts • Cambridge, Massachusetts + 6 more

Conditions: Arnold-Chiari Malformation, Posterior Fossa Tumors
Interventions: IV acetaminophen, normal saline; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 2 Years to 12 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Postoperative Pain Control in Surgical Neonates
Interventions: Ketorolac, placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Week to 3 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 3,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 130
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more

Conditions: Alzheimer Disease
Interventions: TB006, Sterile saline (Placebo); Drug · Other
Lead sponsor: TrueBinding, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Postpartum Depression
Interventions: Ketamine 50 MG/ML, Control; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone; Device · Drug
Lead sponsor: Diane George; Other
Eligibility: Up to 22 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Low Back Pain
Interventions: Adhesiolysis; Procedure
Lead sponsor: Pain Management Center of Paducah; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Paducah, Kentucky

Conditions: Orbital Edema, Orbital Ecchymosis
Interventions: Tranexamic acid injection, Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML), normal saline - injection, normal saline - intravenous; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Obstetric Labour, Premature
Interventions: Retosiban, Atosiban, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Weeks to 20 Weeks
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Park Ridge, Illinois • Galveston, Texas

Conditions: Analgesic Adverse Reaction
Interventions: Ketorolac Tromethamine, 0.9% Normal Saline; Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 2 Years to 18 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Albany, New York

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions: Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 16
States / cities: Los Angeles, California • Sacramento, California • Santa Ana, California + 9 more

Conditions: HIV Infections
Interventions: VRC01, Placebo for VRC01; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 2,699 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more

Conditions: Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2, Type2 Diabetes, Type 2 Diabetes Mellitus, Diabetic Nephropathies, Diabetes Complications
Interventions: Pegloticase 8 MG/ML [Krystexxa]; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 25 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion

Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial

Efficacy of Acetaminophen in Posterior Fossa Surgery

The Use of Ketorolac in Surgical Neonates

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

Ketamine to Prevent PPD After Cesarean

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Role of Steroids and 10% Hypertonic Sodium Chloride in Adhesiolysis in Post Lumbar Surgery Syndrome Patients

The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men

Uric Acid Lowering Trial in Youth Onset T2D